Addex Therapeutics Ltd
SIX:ADXN
Intrinsic Value
Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. [ Read More ]
The intrinsic value of one ADXN stock under the Base Case scenario is 0.3662 CHF. Compared to the current market price of 0.0956 CHF, Addex Therapeutics Ltd is Undervalued by 74%.
Valuation Backtest
Addex Therapeutics Ltd
Run backtest to discover the historical profit from buying and selling ADXN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Addex Therapeutics Ltd
Current Assets | 5.7m |
Cash & Short-Term Investments | 4.8m |
Receivables | 373.4k |
Other Current Assets | 615.2k |
Non-Current Assets | 395.4k |
PP&E | 341.1k |
Other Non-Current Assets | 54.3k |
Current Liabilities | 1.9m |
Accounts Payable | 389.8k |
Accrued Liabilities | 1.3m |
Other Current Liabilities | 206.4k |
Non-Current Liabilities | 262.7k |
Long-Term Debt | 116.9k |
Other Non-Current Liabilities | 145.8k |
Earnings Waterfall
Addex Therapeutics Ltd
Revenue
|
2.5m
CHF
|
Operating Expenses
|
-16.8m
CHF
|
Operating Income
|
-14.4m
CHF
|
Other Expenses
|
-1.1m
CHF
|
Net Income
|
-15.5m
CHF
|
Free Cash Flow Analysis
Addex Therapeutics Ltd
What is Free Cash Flow?
ADXN Profitability Score
Profitability Due Diligence
Addex Therapeutics Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Addex Therapeutics Ltd's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
ADXN Solvency Score
Solvency Due Diligence
Addex Therapeutics Ltd's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Addex Therapeutics Ltd's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ADXN Price Targets Summary
Addex Therapeutics Ltd
According to Wall Street analysts, the average 1-year price target for ADXN is 0.1632 CHF with a low forecast of 0.1616 CHF and a high forecast of 0.168 CHF.
Shareholder Return
ADXN Price
Addex Therapeutics Ltd
Average Annual Return | -30.25% |
Standard Deviation of Annual Returns | 48.17% |
Max Drawdown | -98% |
Market Capitalization | 12.8m CHF |
Shares Outstanding | 134 374 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. The company is headquartered in Plan-Les-Ouates, Geneve and currently employs 28 full-time employees. The company went IPO on 2007-05-22. The firm focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. The company also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.
Contact
IPO
Employees
Officers
The intrinsic value of one ADXN stock under the Base Case scenario is 0.3662 CHF.
Compared to the current market price of 0.0956 CHF, Addex Therapeutics Ltd is Undervalued by 74%.